A combination shot for flu and COVID-19 using messenger RNA generated antibodies in a study, but U.S. government regulators ...

Q1 2025 Earnings Call Transcript May 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.52, expectations were $-2.92. Operator: Good day, and thank you for standing by. Welcome to ...

We recently published a list of the 11 Worst Performing Stocks in S&P 500 So Far in 2025. In this article, we will take a ...

Moderna’s combined Covid and flu shot outperformed the existing standalone vaccines for both viruses, according to the ...

Biotechnology company Moderna (NASDAQ:MRNA) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 35.3% year on year to $108 million. The company’s full-year revenue ...

Moderna MRNA kicked off 2025 with mixed first-quarter results. While its streamlining efforts improved bottom-line numbers, the steep decline in revenues raises concerns. While sales of its COVID ...

In a study published in the Journal of the American Medical Association, researchers from Moderna reported that the new combo ...

Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ETCompany ParticipantsLavina Talukdar - Senior Vice President, ...

This particularly impacts Moderna, as it is predominantly focused on mRNA vaccines. The big one I've been watching is its combination vaccine that targets both influenza and COVID-19 with just one ...

Moderna MRNA incurred a loss of $2.52 per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $2.92. In the year-ago period, the company had reported a loss ...